1st Line Durvalumab in PS 2 NSCLC Patients

Sponsor
Swiss Cancer Institute
Study ID
NCT03620669
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • NSCLC Stage IIIB
  • NSCLC Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Durvalumab 1500mg q4W until progression or unacceptable toxicity

Study Details

The aim of the trial is to assess efficacy and safety of the treatment with durvalumab in PS 2 patients with treatment-naïve, locally advanced or metastatic, PD-L1 positive NSCLC who are considered unsuitable for combination platinum-containing therapy.

Key Dates

Start date
Dec 4, 2018
Status verified
Aug 2025
Primary completion
Jan 19, 2023
Completion
Sep 30, 2027

Study Design

Enrollment
48 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab
    Durvalumab until progression or unacceptable toxicity

Primary Outcome Measure

Overall survival (OS) at 6 months [ Time Frame: At 6 months after registration ]

Related Studies